Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease

Benzer Materyaller

• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  Yazar:: Bekker, P, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
  Yazar:: Walters, M, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
  Yazar:: Ungashe, S, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
  Yazar:: Satish Keshav, ve diğerleri
  Baskı/Yayın Bilgisi: (2013-01-01)
• PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
  Yazar:: Bekker, P, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)